CAS 1639422-97-1

Fórmula: C28H27N5O2

InChI: InChI=1S/C28H27N5O2/c1-6-17-10-21-22(11-20(17)18-13-30-33(14-18)15-24(34)32(4)5)28(2,3)27-25(26(21)35)19-8-7-16(12-29)9-23(19)31-27/h7-11,13-14,31H,6,15H2,1-5H3

Chave InChI: IDGNCVHQDDOPND-UHFFFAOYSA-N

SMILES: CCC1=CC2=C(C=C1C3=CN(N=C3)CC(=O)N(C)C)C(C4=C(C2=O)C5=C(N4)C=C(C=C5)C#N)(C)C

JH-VIII-157-02

CAS: 1639422-97-1

JH-VIII-157-02

Fórmula: C₂₈H₂₇N₅O₂

Pureza: 99.5%

Peso molecular: 465.55

Ref: 54-BUP08623

JH-VIII-157-02

CAS: 1639422-97-1

Fórmula: C₂₈H₂₇N₅O₂

Peso molecular: 465.5463

Ref: IN-DA01EO8R

2-(4-(3-Cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)-1H-pyrazol-1-yl)-N,N-dimethylacetamide

CAS: 1639422-97-1

2-(4-(3-Cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)-1H-pyrazol-1-yl)-N,N-dimethylacetamide

Fórmula: C₂₈H₂₇N₅O₂

Pureza: 98%

Peso molecular: 465.55

Ref: IN-DG00799027

JH-VIII-157-02

CAS: 1639422-97-1

JH-VIII-157-02 is an analog of alectinib, a drug that binds to the kinase domain of tyrosine kinases, inhibiting their activity. The tyrosine kinases are involved in many cellular processes such as cell growth and differentiation. JH-VIII-157-02 has shown activity against non-small cell lung cancer cells and has been studied in clinical trials for its efficacy against this disease. It is believed that the drug blocks constitutive activation of the protein by binding to the kinase domain and preventing it from interacting with other proteins. The molecule also inhibits the phosphorylation of other proteins, leading to tumor growth inhibition.

Fórmula: C₂₈H₂₇N₅O₂

Pureza: Min. 95%

Peso molecular: 465.5 g/mol

Ref: 3D-PQC42297

JH-VIII-157-02

CAS: 1639422-97-1

JH-VIII-157-02 inhibits ALK, specifically EML4-ALK variants, with IC50s of 2 nM.

Fórmula: C₂₈H₂₇N₅O₂

Pureza: 99.58%

Cor e Forma: Solid

Peso molecular: 465.5463

Ref: TM-T15612